Retatrutide 30mg

Retatrutide is a synthetic 39-amino-acid peptide constructed on a glucose-dependent insulinotropic polypeptide (GIP) backbone with α-aminoisobutyric acid (Aib) substitutions at selected positions. A C20 diacid lipid chain is attached at a lysine side chain by way of a γ-glutamate and OEG spacer. This listing supplies the same chemical entity as the 10mg vial at a 30mg fill weight; the product name across title, listing and label is Retatrutide.

The molecular targets characterised in vitro are three class B1 G-protein-coupled receptors: the GIP receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Affinity at each receptor is measured by competitive displacement against membranes from cells recombinantly expressing that single receptor. Functional occupancy is recorded as cAMP accumulation with EC50 values determined per receptor system, and as beta-arrestin recruitment measured in complementation assays. Every figure discussed is a reading taken from a defined recombinant cell line.

Peer-reviewed work on Aib-constrained peptide backbones, lipidation chemistry and class B1 receptor pharmacology is indexed in PubMed, with identifier and structural records in PubChem and ChEMBL. Search results and cited literature do not establish the performance of a commercial lot or a use recommendation.